Compare Bank of Montreal (BMO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Summit Therapeutics Inc — how do they compare? Bank of Montreal trades at $182.32 (market cap $126.83B), while Summit Therapeutics Inc trades at $15.45 (market cap $12.06B). The key difference: Bank of Montreal is far larger — about 10.5× Summit Therapeutics Inc's market cap, and Bank of Montreal pays a 2.69% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BMO | SMMT | |
|---|---|---|
Market Cap | $126.83B | $12.06B |
Sector | Financials | Health |
52-Week High | $183.65 | $26.98 |
52-Week Low | $112.54 | $12.55 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $181.91, up 0.2% today, with a bullish technical signal from moving averages and support near $181. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.68 exceeding the $2.54 estimate. Revenue grew to $36.10B in 2025, and net income margin improved to 24.12%. Recent news includes the sale of Moneris for $1.44B and the launch of new ETNs with REX Shares.
Outlook is supported by consistent earnings performance and strategic initiatives, but risks include interest rate sensitivity and macroeconomic pressures. Analysts are divided with a Hold consensus, reflecting balanced optimism and caution. The stock's valuation at a P/E of 19.41 appears reasonable given profitability trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
